Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis

Diabetes Care

Volumn 27, Issue 8, 2004, Pages 2057-2066

  Medina, Jesús ^a   Fernández Salazar, Luis I ^b   García Buey, Luisa ^a   Moreno Otero, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; ALPHA TOCOPHEROL; AMIODARONE; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; AUTACOID; BETA CAROTENE; CHOLINE; CLOFIBRATE; CYTOKINE; FATTY ACID; GEMFIBROZIL; GHRELIN; IRON; METADOXINE; METRONIDAZOLE; PERHEXILINE MALEATE; PHOSPHATIDYLCHOLINE; POLYMYXIN B; PROBIOTIC AGENT; PROTECTIVE AGENT; S ADENOSYLMETHIONINE; SELENIUM; SILYMARIN; TAMOXIFEN; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ALCOHOL ABUSE; BACTERIAL OVERGROWTH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG INDICATION; EXERCISE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; IRON STORAGE; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW CALORY DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PARENTERAL NUTRITION; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; TREATMENT INDICATION;

ALCOHOLISM; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL;

EID: 3342958806     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.8.2057     Document Type: Review

References (123)

1. Neuschwander-Tetri BA, Caldwell S: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202-1219, 2003
2. Clark JM, Brancati F, Diehl A: The prevalence and etiology of elevated amino-transferase levels in the United States. Am J Gastroenterol 98:960-967, 2003
3. Clark JM, Brancati F, Diehl A: Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657, 2002
4. Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J, Hui J, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35: 373-379, 2002
5. Willner IR, Waters B, Patil S, Reuben A, Morelli J, Riely C: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96:2957-2961, 2001
6. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo W, Contos M, Sterling R, Luketic V, Shiffman M, Clore J: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192, 2001
7. Dixon JB, Bhathal P, O'Brien P: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001
8. Valenti L, Fracanzani A, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S: Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122:274-280, 2002
9. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35:367-372, 2002
10. Wanless IR, Lentz J: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106-1110, 1990
11. Falck-Ytter Y, Younossi Z, Marchesini G, McCullough A: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17-26, 2001
12. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T: Liver fibrosis in overweight patients. Gastroenterology 118:1117-1123, 2000
13. Garcia-Monzon C, Martin-Perez E, Iacono O, Fernandez-Bermejo M, Majano P, Apolinario A, Larranaga E, Moreno-Otero R: Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33:716-724, 2000
14. Day CP: Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 50:585-588, 2002
15. Alba LM, Lindor K: Non-alcoholic fatty liver disease (Review Article). Aliment Pharmacol Ther 17:977-986, 2003
16. Angulo P, Keach J, Batts K, Lindor K: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356-1362, 1999
17. Brunt EM, Janney C, Bisceglie AD, Neuschwander-Tetri B, Bacon B: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474, 1999
18. Day CP, James O: Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845, 1998
19. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough A, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850, 2001
20. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923, 2003
21. Matteoni CA, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999
22. Savage DB, Tan G, Acerini C, Jebb S, Agostini M, Gurnell M, Williams R, Umpleby A, Thomas E, Bell J, Dixon A, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee V, O'Rahilly S: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 52:910-917, 2003
23. Reynet C, Kahn C: Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans. Science 262: 1441-1444, 1993
24. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Stewart T, et al.: Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 373:448-451, 1995
25. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z, Karin M, Shoelson S: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673-1677, 2001
26. Uysal KT, Wiesbrock S, Marino M, Hotamisligil G: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389: 610-614, 1997
27. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante J, Pons-Romero F: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34: 1158-1163, 2001
28. Mezey E: Dietary fat and alcoholic liver disease. Hepatology 28:901-905, 1998
29. Musso G, Gambino R, Michieli FD, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:909-916, 2003
30. Jensen MD, Haymond M, Rizza R, Cryer P, Miles J: Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83:1168-1173, 1989
31. Arner P: Not all fat is alike. Lancet 351: 1301-1302, 1998
32. Powell EE, Searle J, Mortimer R: Steatohepatitis associated with limb lipodystrophy. Gastroenterology 97:1022-1024, 1989
33. Friedman JM, Halaas J: Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998
34. Lee Y, Wang M, Kakuma T, Wang Z, Babcock E, McCorkle K, Higa M, Zhou Y, Unger R: Liporegulation in diet-induced obesity: the antisteatotic role of hyperleptinemia. J Biol Chem 276:5629-5635, 2001
35. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci M, Bagci S, Gulsen M, Karaeren N, Dagalp K: Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95:3584-3589, 2000
36. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, Liddle C, Samarasinghe D, George J: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36:403-409, 2002
37. Cohen B, Novick D, Rubinstein M: Modulation of insulin activities by leptin. Science 274:1185-1188, 1996
38. Chalasani N, Crabb D, Cummings O, Kwo P, Asghar A, Pandya P, Considine R: Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 98:2771-2776, 2003
39. Galli A, Pinaire J, Fischer M, Dorris R, Crabb D: The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism: a novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 276:68-75, 2001
40. Berson A, Beco VD, Letteron P, Robin M, Moreau C, Kahwaji JE, Verthier N, Feldmann G, Fromenty B, Pessayre D: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764-774, 1998
41. Kaplan LM: Leptin, obesity, and liver disease. Gastroenterology 115:997-1001, 1998
42. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair K: Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35:898-904, 2002
43. Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, Rizzetto M, Pagano G: Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 36:1117-1124, 2001
44. Clarke SD: Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 281:G865-G869, 2001
45. Unger RH, Orci L: Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585:202-212, 2002
46. Rashid A, Wu T, Huang C, Chen C, Lin H, Yang S, Lee F, Diehl A: Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 29:1131-1138, 1999
47. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M: Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39:179-187, 2004
48. Pessayre D, Berson A, Fromenty B, Mansouri A: Mitochondria in steatohepatitis. Semin Liver Dis 21:57-69, 2001
49. Pessayre D, Mansouri A, Fromenty B: Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 282:G193-G199, 2002
50. Reddy JK: Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 281:G1333-G1339, 2001
51. Hruszkewycz AM: Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 153:191-197, 1988
52. Leclercq IA, Farrell G, Field J, Bell D, Gonzalez F, Robertson G: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105:1067-1075, 2000
53. Chalasani N, Gorski J, Asghar M, Asghar A, Foresman B, Hall S, Crabb D: Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37:544-550, 2003
54. Robertson G, Leclercq I, Farrell G: Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281:G1135-G1139, 2001
55. Weltman MD, Farrell G, Hall P, Ingelman-Sundberg M, Liddle C: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128-133, 1998
56. Chavin KD, Yang S, Lin H, Chatham J, Chacko V, Hoek J, Walajtys-Rode E, Rashid A, Chen C, Huang C, Wu T, Lane M, Diehl A: Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 274:5692-5700, 1999
57. Echtay KS, Roussel D, St-Pierre J, Jekabsons M, Cadenas S, Stuart J, Harper J, Roebuck S, Morrison A, Pickering S, Clapham J, Brand M: Superoxide activates mitochondrial uncoupling proteins. Nature 415:96-99, 2002
58. Cortez-Pinto H, Chatham J, Chacko V, Arnold C, Rashid A, Diehl A: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282:1659-1664, 1999
59. Baffy G, Zhang C, Glickman J, Lowell B: Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 35:753-761, 2002
60. Zeviani M, Tiranti V, Piantadosi C: Mitochondrial disorders. Medicine (Baltimore) 77:59-72, 1998
61. Kern PA, Saghizadeh M, Ong J, Bosch R, Deem R, Simsolo R: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995
62. Tilg H, Diehl A: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343:1467-1476, 2000
63. Shepherd PR, Kahn B: Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-257, 1999
64. Bernard S, Touzet S, Personne I, Lapras V, Bondon P, Berthezene F, Moulin P: Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43:995-999, 2000
65. Masuzaki H, Paterson J, Shinyama H, Morton N, Mullins J, Seckl J, Flier J: A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001
66. Barsh GS, Farooqi I, O'Rahilly S: Genetics of body-weight regulation. Nature 404:644-651, 2000
67. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht R, Banner B: Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31:421-429, 1999
68. Chitturi S, Weltman M, Farrell G, McDonald D, Kench J, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J: HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36:142-149, 2002
69. George DK, Goldwurm S, MacDonald G, Cowley L, Walker N, Ward P, Jazwinska E, Powell L: Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114:311-318, 1998
70. Grove J, Daly A, Bassendine M, Day C: Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26:143-146, 1997
71. Grove JJ, Daly A, Bassendine M, Gilvarry E, Day C: Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46:540-545, 2000
72. Mendler MH, Turlin B, Moirand R, Jouanolle A, Sapey T, Guyader D, Gall JL, Brissot P, David V, Deugnier Y: Insulin resistance-associated hepatic iron overload. Gastroenterology 117:1155-1163, 1999
73. Moirand R, Mortaji A, Loreal O, Paillard F, Brissot P, Deugnier Y: A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349:95-97, 1997
74. Chitturi S, George J: Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 5:18-25, 2003
75. Fargion S, Mattioli M, Fracanzani A, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96:2448-2455, 2001
76. Ludwig J, Hashimoto E, Porayko M, Moyer T, Baldus W: Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 112:882-888, 1997
77. Younossi ZM, Gramlich T, Bacon B, Matteoni C, Boparai N, O'Neill R, McCullough A: Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30:847-850, 1999
78. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34:738-744, 2001
79. Saxena NK, Ikeda K, Rockey D, Friedman S, Anania F: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35: 762-771, 2002
80. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N: Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36:12-21, 2002
81. Solga SF, Diehl A: Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 38:681-687, 2003
82. Wigg AJ, Roberts-Thomson I, Dymock R, McCarthy P, Grose R, Cummins A: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206-211, 2001
83. Drenick EJ, Fisler J, Johnson D: Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82:535-548, 1982
84. Adachi Y, Moore L, Bradford B, Gao W, Thurman R: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108: 218-224, 1995
85. Yin M, Wheeler M, Kono H, Bradford B, Gallucci R, Luster M, Thurman R: Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117:942-952, 1999
86. Chitturi S, Farrell G: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21:27-41, 2001
87. Yang SQ, Lin H, Lane M, Clemens M, Diehl A: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94:2557-2562, 1997
88. Loffreda S, Yang S, Lin H, Karp C, Brengman M, Wang D, Klein A, Bulkley G, Bao C, Noble P, Lane M, Diehl A: Leptin regulates proinflammatory immune responses. FASEB J 12:57-65, 1998
89. Li Z, Lin H, Yang S, Diehl A: Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 123:1304-1310, 2002
90. Nair S, Cope K, Risby T, Diehl A, Terence R: Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 96:1200-1204, 2001
91. Koteish A, Diehl A: Animal models of steatosis. Semin Liver Dis 21:89-104, 2001
92. Cope K, Risby T, Diehl A: Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 119:1340-1347, 2000
93. Poullis A, Mendall M: Alcohol, obesity, and TNF-alpha. Gut 49:313-314, 2001
94. Kugelmas M, Hill D, Vivian B, Marsano L, McClain C: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38: 413-419, 2003
95. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103-107, 1997
96. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99:1408-1413, 1990
97. Drenick EJ, Simmons F, Murphy J: Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 282: 829-834, 1970
98. Neuschwander-Tetri BA, Bacon E: Nonalcoholic steatohepatitis. Med Clin North Am 80:1147-1166, 1996
99. Laurin J, Lindor K, Crippin J, Gossard A, Gores G, Ludwig J, Rakela J, McGill D: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23:1464-1467, 1996
100. Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31:384, 1999
101. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H: Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353:1802, 1999
102. Harrison SA, Ramrakhiari S, Brunt E, Anbari M, Cortese C, Bacon B: Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 98:926-930, 2003
103. Li Z, Yang S, Lin H, Huang J, Watkins P, Moser A, Desimone C, Song X, Diehl A: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343-350, 2003
104. Sheth SG, Gordon F, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145, 1997
105. Ludwig J, McGill D, Lindor K: Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 12:398-403, 1997
106. Loguercio C, Simone TD, Federico A, Terracciano F, Tuccillo C, Chicco MD, Carteni M: Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 97:2144-2146, 2002
107. Lindor KD, Kowdley K, Heathcote E, Harrison M, Jorgensen R, Angulo P, Lymp J, Burgart L, Colin P: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:770-778, 2004
108. Osman E, Owen J, Burroughs A: S-adenosyl-L-methionine: a new therapeutic agent in liver disease? (Review Article) Aliment Pharmacol Ther 7:21-28, 1993
109. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A: Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15: 1667-1672, 2001
110. Caballeria J, Pares A, Bru C, Mercader J, Garcia-Plaza A, Caballeria L, Clemente G, Rodrigo L, Rodes J: Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial: Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 28:54-60, 1998
111. Flora K, Hahn M, Rosen H, Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139-143, 1998
112. Abdelmalek MF, Angulo P, Jorgensen R, Sylvetre P, Lindor K: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96:2711-2717, 2001
113. Bugranesi E, Marchesini G, Pagotto U: Ghrelin in non-alcoholic fatty liver disease (Abstract). J Hepatol 38:A-3620, 2003
114. Satapathy SK, Garg S, Sakhuja P, Malhatra V, Sorin S: Pentoxyphylline as a novel therapy for non-alcoholic steatohepatitis: a pilot study (Abstract). Gastroenterology 124:A-728, 2003
115. Caldwell SH, Hespenheide E, Redick J, Iezzoni J, Battle E, Sheppard B: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519-525, 2001
116. Neuschwander-Tetri BA, Brunt E, Wehmeier K, Oliver D, Bacon B: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017, 2003
117. Neuschwander-Tetri BA, Brunt E, Wehmeier K, Sponseller C, Hampton K, Bacon B: Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38:434-440, 2003
118. Promrat K, Lutchman G, Uwaifo G, Freedman R, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang T, Janovski J, Kleiner D, Hoofnagle J: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004
119. Kirpichnikov D, McFarlane S, Sowers J: Metformin: an update. Ann Intern Med 137:25-33, 2002
120. Lin HZ, Yang S, Chuckaree C, Kuhajda F, Ronnet G, Diehl A: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998-1003, 2000
121. Marchesini G, Brizi M, Bianchi G, Tomasetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894, 2001
122. Uygun A, Kadayifci A, Isik A, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19: 537-544, 2004
123. D'Souza-Gburek SM, Batts K, Nikias G, Wiesner R, Krom R: Liver transplantation for jejunoileal bypass-associated cirrhosis: allograft histology in the setting of an intact bypassed limb. Liver Transpl Surg 3:23-27, 1997